Table 1 Studies of pre-ASCT treatment intensification in MM.

From: Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma

Study

Methods

Initial response

Intensified cohort

Other cohort

Outcome

Vij 2015 [17]

Retrospective CIBMTR registry

≤MR to a PI- or IMID-containing regimen

Second-line therapy leading into ASCT

Direct transition to ASCT

No difference in PFS or OS with addition of second-line therapy

Jackson 2019 [18]

Prospective randomized trial

≤PR to CTd or CRd

Second-line CyBorD leading into ASCT

Direct transition to ASCT

Increased PFS, but no increased OS, with additional CyBorD

  1. ASCT autologous stem cell transplantation, CIBMTR Center for International Blood and Marrow Transplant Research, CRd cyclophosphamide/lenalidomide/dexamethasone, CTd cyclophosphamide/thalidomide/dexamethasone, CyBorD cyclophosphamide/bortezomib/dexamethasone, MM multiple myeloma, MR minimal response, OS overall survival, PD progressive disease, PR partial response, PFS progression-free survival, SD stable disease.
Back to article page